You are here

Share:

New Mouse T Cell Receptors as Potential Therapeutic Agents for the Treatment of Metastatic Cancer

Summary
Researchers at the NCI have developed novel T Cell Receptors that target the melanoma antigen, gp100, expressed by human cancers. These TCRs provide superior biological function making them ideal for adoptive immunotherapy. NCI Seeks parties to license or co-develop these TCRs.
NIH Reference Number
E-059-2007
Product Type
Keywords
  • immunotherapy, TCR, gp100
Collaboration Opportunity
This invention is available for licensing and co-development.
Contact
Description of Technology

Adoptive immunotherapy is one of the most promising new therapeutic approaches to treat cancer. T cell receptors (TCR) are the proteins responsible for the T cell's ability to recognize infected or transformed cells. A TCR consists of two domains, one variable domain that recognizes the antigen and one constant region that helps the TCR anchor to the membrane and transmit the recognition signal by interacting with other proteins.

This invention describes the identification of two mouse TCRs that target a common and highly expressed melanoma antigen, gp100, expressed by human cancers. These TCRs, have superior (100-1000 times) biological function compared to other human tumor-specific TCR that are currently in use in experimental trials using genetically engineered T cells. Therefore, these new TCRs represent potential therapeutic agents that can be used in the treatment of metastatic cancers, especially melanomas.

Potential Commercial Applications
  • New mouse TCRs have been identified that recognize human gp100.
  • The mouse TCRs have 100-1000 times superior biological function compared to their human counterpart in recognizing gp100 when expressed in human lymphocytes.
  • Human T cells genetically engineered to express new TCRs can serve as potential therapeutic agents in the treatment of patients with metastatic cancers. 
  • Clinical trials with these novel TCRs.
Competitive Advantages
  • Reduced side-effects compared to those associated with anti-cancer drugs and radiation therapy.
Development Stage
Patent Status
  • U.S. Patent Issued: U.S. Patent Number
  • Foreign Issued: - Patent Number CA 2674445, Filed 03 Jul 2009, Issued 07 Jun 2016
  • U.S. Patent Issued: U.S. Patent Number
Therapeutic Area
Updated
Tuesday, April 3, 2018